SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

NCT04803877 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Osteosarcoma
Osteosarcoma in Children
Osteosarcoma Recurrent
Osteosarcoma Metastatic

Interventions

DRUG: Regorafenib 40 MG
DRUG: Regorafenib 20MG
DRUG: Nivolumab

Sponsor

Sarcoma Alliance for Research through Collaboration